Lombard Medical Technologies (NSDQ:EVAR) said today it completed a restructuring of its business after implementing a plan to focus its sales efforts on the UK, Japan and China, as well as reducing operating and manufacturing costs as it seeks to breakeven with its cash flow. The UK-based company said that the restructuring is expected to result […]
MicroPort Scientific
MicroPort Orthopedics launches Procotyl Prime hip system
MicroPort Orthopedics said today it launched its Procotyl Prime acetabular cup system. The Arlington, Tenn.-based company won FDA 510(k) clearance for the system in late June, and said that the system is the next step in the evolution of its Dynasty acetabular cup system. “At MicroPort Orthopedics, we embrace the constant advance in orthopedic medicine, […]
Lombard, MicroPort finalize strategic partnership
Lombard Medical Technologies (NSDQ:EVAR) said today it finalized a strategic partnership deal with MicroPort Scientific. Through the partnership, MicroPort will manufacture certain components for Lombard’s Aorfix and Altura product lines at its Shanghai facilities, slated to begin in the 2nd half of this year. “This strategic partnership begins to establish the foundation for improved gross margins […]
MicroPort Orthopedics touts high satisfaction, survivorship in Medial-Pivot knee system study
MicroPort Orthopedics today released the results from a study of its Medial-Pivot knee system, touting high rates of satisfaction and survivorship at 17 years. Results from the trial, including long-term clinical and radiographic outcomes, were publsiehd in the medical journal The Knee. Data from the 325 patient trial exploring patients with knee osteoarthritis who underwent total […]
MicroPort, undaunted by price caps, enters India’s stent market
MicroPort has entered the Indian market only days after the country’s National Pharmaceutical Pricing Authority imposed a price cap on coronary stents. The Shanghai-based company said its Firehawk Rapamycin target eluting coronary stent system was successfully used in a procedure in Mumbai earlier in the month, marking the 1st time the device saw use in […]
China’s Microport puts $15m into Lombard Medical
Lombard Medical Technologies (NSDQ:EVAR) said today that China’s MicroPort Orthopedics invested $15 million as part of a partnership deal between the 2 companies. Through the partnership, Lombard will seek to accelerate commercialization of its Aorfix and Altura stent grafts for treating abdominal aortic aneurysms. Microport will gain exclusive marketing rights for both products in China and Brazil, as […]
Novartis pharma head Epstein steps away, most recent in string of top-level turnovers | Personnel Moves, May 27, 2015
Novartis pharma head Epstein steps away, most recent loss in string of top-level turnovers Novartis (NYSE:NVS) is facing an upheaval in its top management, seeing 7 departures over the last 5 months as shares fell 25% since last July. Last week, Novartis pharmaceuticals head David Epstein quit as his division was split up. Earlier in the month, U.S. […]
Fracture rate prompts recall for MicroPort’s ProFemur hip implant
The FDA said last Friday it is recalling MicroPort Orthopedics ProFemur long cobalt chrome 8 degree Varus and Valgus modular neck implants over issues with the acute fractures. The federal watchdog labeled the recall as a Class I, the most serious type of recall issued by the FDA, which indicates “there is a reasonable probability that […]
MicroPort launches Profemur Preserve hip stem
MicroPort Orthopedics said today it launched the Profemur Preserve hip stem for use in hip replacement procedures. The Profemur Preserve is designed with a shorter stem, which are moree commonly used in younger patient populations to preserve bone for future revisions and treatments, Arlington, Tenn.-based MicroPort said. “As physicians evaluate the landscape of short stems, Profemur […]
Wright Medical, ConforMIS settle patent dispute
BioVentrix raises $12M for heart attack treatment | MassDevice.com On Call
MASSDEVICE ON CALL — BioVentrix reported a $12.4 million funding round for its Revivent heart failure treatment.
San Ramon, Calif.-based BioVentrix said in an equity filing that the equity round, involving 195 unnamed investors, began Jan. 24 and closed today.